Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type: A case series and review of the literature.

Détails

Ressource 1Télécharger: 39031169.pdf (6781.68 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_565A788D2615
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type: A case series and review of the literature.
Périodique
The Journal of dermatology
Auteur⸱e⸱s
Winkler M., Albrecht J.D., Sauer C., Kordaß T., Guenova E., Livingstone E., Wobser M., Mitteldorf C., Géraud C., Nicolay J.P.
ISSN
1346-8138 (Electronic)
ISSN-L
0385-2407
Statut éditorial
Publié
Date de publication
09/2024
Peer-reviewed
Oui
Volume
51
Numéro
9
Pages
1233-1239
Langue
anglais
Notes
Publication types: Case Reports ; Review ; Journal Article
Publication Status: ppublish
Résumé
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT) is a subtype of cutaneous B-cell lymphoma with unfavorable prognosis usually requiring aggressive polychemotherapy for disease control. Only single cases of spontaneous regression of PCDLBCL, LT are reported in the literature, peaking 3 months post-biopsy following a clinical history of no longer than 1 year. Here, we report the first case of a spontaneously relapsing and remitting PCDLBCL, LT with complete regression after a clinical history of more than 9 years and thus an atypically indolent clinical course. The female patient presented with recurrent erythematous, non-ulcerated, non-raised plaques of the right lower leg for 6 years. Pathological workup and exclusion of a systemic disease confirmed the diagnosis of PCDLBCL, LT. Due to the history of repeated spontaneous remission, no therapy was initiated. Nine years after first occurrence the patient presented with complete clinical remission lasting for 64 months. We retrospectively identified four additional PCDLBCL, LT patients with spontaneous remission lasting up to 53 months. Our data provide evidence for a distinct PCDLBCL, LT patient subgroup that clinicians should be aware of and warrants a watch-and-wait treatment regime.
Mots-clé
Humans, Female, Lymphoma, Large B-Cell, Diffuse/pathology, Lymphoma, Large B-Cell, Diffuse/drug therapy, Lymphoma, Large B-Cell, Diffuse/diagnosis, Skin Neoplasms/pathology, Skin Neoplasms/diagnosis, Leg/pathology, Neoplasm Regression, Spontaneous, Aged, Middle Aged, Remission, Spontaneous, Skin/pathology, Biopsy, diffuse large B‐cell lymphoma, leg dermatoses, lymphoma, skin neoplasms, spontaneous neoplasm regression
Pubmed
Web of science
Open Access
Oui
Création de la notice
26/07/2024 13:20
Dernière modification de la notice
10/09/2024 6:23
Données d'usage